Lates News

Hansen Pharmaceuticals announced that its independently developed new drug HS-10587 tablets have obtained the drug clinical trial approval notification issued by the China National Medical Products Administration. It is intended to conduct clinical trials for late-stage solid tumors with MTAP deficiency.